We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Elevated Levels of Beta-2 Microglobulin Linked to Increased Stroke Risk

By LabMedica International staff writers
Posted on 22 May 2017
Beta-2 microglobulin, also known as B2M, is a component of the MHC class I molecules, which are present on all nucleated cells. More...
They also occur on platelets, but not on red blood cells. Their function is to display peptide fragments of non-self-proteins from within the cell to cytotoxic T-cells; this will trigger an immediate response from the immune system against a particular non-self-antigen displayed with the help of an MHC class I protein.

As recent studies had found associations between beta-2 microglobulin and heart disease, investigators at Harvard Medical School decided to study the association between beta-2 microglobulin and ischemic stroke.

The investigators measured B2M levels in 473 ischemic strokes cases confirmed by medical record review and in 473 controls matched 1:1 to the cases on age, race, date of blood collection, menopausal status, postmenopausal hormone use, and smoking status. The subjects were women with an average age of 61 who provided blood samples between 1989 and 1990 and who had no history of stroke or cancer. Participants completed questionnaires about their lifestyle and medical history every two years. The investigators analyzed the association between B2M and ischemic stroke using multivariable conditional logistic regression to adjust for traditional stroke risk factors.

Results revealed that participants who later had an ischemic stroke had higher levels of beta-2 microglobulin than those who did not have a stroke. The average level of the protein was 1.86 milligrams per liter in those who had ischemic strokes, compared to 1.80 milligrams per liter in those who did not have a stroke. Those in the highest quarter of beta-2 microglobulin levels were 56% more likely to have a stroke than those in the bottom quarter. In the top quarter, 163 of the 283 women had strokes, compared to 106 of the 227 women in the bottom quarter.

“Recent studies have found associations between beta-2 microglobulin and heart disease,” said first author Dr. Pamela Rist, instructor in medicine and epidemiology at Harvard Medical School. “However, less is known about the association between beta-2 microglobulin and ischemic stroke. Given the high rate of disability from stroke, it is important to identify people who may be at higher risk of this disease. This protein could be a marker that might help us in the fight against stroke. Further studies are needed to determine if beta-2 microglobulin levels can be modified through lifestyle changes.”

The study was published in the May 10, 2017, online issue of the journal Neurology.


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Vasculitis Diagnostic Test
AESKULISA Vasculitis-Screen
New
C-Reactive Protein Rapid Test
Afinion CRP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.